Anteris announces results for the second quarter of 2025

Minneapolis and brisbane, australia, aug. 11, 2025 (globe newswire) -- anteris technologies global corp. (anteris or the company) (nasdaq: avr, asx: avr) a global structural heart company committed to designing, developing, and commercialising cutting-edge medical devices to restore healthy heart function, today reported financial results for the quarter ended june 30, 2025, and provided a corporate update. second quarter 2025 highlights 130 patients implanted with the duravr® thv since the start of clinical development; 49 patients treated year-to-date; 21 in the quarter world first “double duravr®” implant in a patient receiving a valve-in-valve replacement in both the mitral and aortic valve positions advanced preparatory work for the duravr® thv's global, pivotal clinical trial (the "paradigm trial") including qualifying additional clinical sites (79 sites now qualified) held global investigator meeting for the paradigm trial in june, with dr. michael j.
AVR Ratings Summary
AVR Quant Ranking